BeiGene
BeiGene, Ltd. is a global biotechnology company founded in 2010, focused on the discovery and development of innovative oncology treatments aimed at improving accessibility and affordability for cancer patients worldwide. Based in Beijing, with a presence in the United States and beyond, BeiGene has established one of the largest oncology research teams globally, employing over 9,200 professionals. The company’s commercial portfolio includes BRUKINSA, a BTK inhibitor approved for various blood cancers, and Tislelizumab, an anti-PD-1 antibody currently under regulatory review for advanced esophageal squamous cell carcinoma. BeiGene's extensive pipeline encompasses a wide range of cancer therapies targeting multiple malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors. In addition to its therapeutic development, the company actively engages in programs that address the broader needs of oncology patients, such as mental health awareness initiatives. Through its commitment to innovation and patient care, BeiGene aims to significantly impact cancer treatment and improve outcomes for patients around the globe.
Top Stages
5 past transactions
Duo Oncology
Seed Round in 2023
Duo Oncology is a biotechnology company focused on developing innovative nanoparticle technology designed to penetrate established tumors, particularly targeting hard-to-treat cancers such as pancreatic cancer and bile duct cancer. By collaborating closely with leading university scientists and medical oncologists, Duo Oncology aims to redefine treatment outcomes through a novel monotherapy approach that enhances patient care. The company's research is supported by a network of established research organizations, enabling efficient and rapid development of its products. With a commitment to advancing immunotherapy and precision medicine, Duo Oncology seeks to improve recovery times and overall treatment efficacy for patients facing challenging diagnoses.
Strand Therapeutics
Series A in 2021
Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.
Boston Immune Technologies & Therapeutics
Series A in 2021
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.
Singlomics
Series A in 2020
Singlomics is a biotechnology company that leverages single-cell sequencing technology to develop innovative antibody drugs aimed at treating infectious diseases and cancers. The company focuses on the discovery and development of neutralizing antibodies, including DXP593 and DXP604, which serve as potential therapeutic solutions against COVID-19. By utilizing advanced sequencing techniques, Singlomics aims to enhance the efficacy of antibody treatments and address significant health challenges in infectious diseases and oncology.
Leap Therapeutics
Post in 2020
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of targeted and immuno-oncology therapies for cancer treatment. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company focuses on identifying and developing molecules that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1) and is currently undergoing clinical trials for various cancers, including esophagogastric and gynecologic cancers. Additionally, Leap Therapeutics is advancing its second program, FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative treatments for cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.